Sarcopenia in Acute Ischemic Stroke

Sarcopenia in Patients During the Acute Phase of Ischemic Stroke: Multimodal Assessment and Three-Month Functional Outcomes

Registry ID
NCT07764172
Source registry
NCT
Status
RECRUITING
Study type
OBSERVATIONAL
Sponsor
University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)
Enrollment
400
Start date
2026-08-01
Completion date
2029-12-31
Last update
2026-08-13

Conditions

Summary

The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental verification and functional-cognitive assessments, and to evaluate its impact on functional outcome at three months. The main research question is: Is the presence of sarcopenia at admission associated with less favorable stroke outcomes, including higher rates of complications and mortality? Participants receiving standard medical care for acute ischemic stroke will undergo extended functional assessment for sarcopenia, and a subset will additionally undergo cognitive evaluation.

Inclusion criteria

Inclusion Criteria: * Age 50 years and older * Acute ischemic stroke confirmed by CT or MRI * Admission within the first 72 hours * Written informed consent and availability of a contact telephone number for follow-up

Exclusion criteria

Exclusion Criteria: * TIA without a visible lesion on neuroimaging; bilateral hemiparesis * Amputations or severe contractures that preclude anthropometric assessment * Active cancer at stage IV or life expectancy of less than 3 months * Neuromuscular diseases; chronic use of systemic glucocorticoids for more than 3 months * Pregnancy; refusal to participate Discontinuation criteria (drop-out) * Discharge or death within the first 7 days * Withdrawal of consent * Transfer to another facility resulting in loss of contact

Primary outcomes

[{"measure":"Change from Baseline in Barthel Index for Activities of Daily Living at 14 days","timeFrame":"Baseline and 14 days"},{"measure":"Change from Baseline in Modified Rankin scale at 90 days","timeFrame":"Baseline and 90 days"}]

Locations

Related clinical trials

View on source registry